1-2 of 2
Andrzej Hellmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2219–2229.
https://doi.org/10.1182/bloodadvances.2021006138
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2207–2218.
https://doi.org/10.1182/bloodadvances.2021005487
Published: 2022
Includes: Supplemental data